Amylyx Pharmaceuticals, Inc. (AMLX) Insider Transactions

Insider purchases & sales, cluster activity

AMLX Insider Buying & Selling Activity

Between Aug 12, 2025 and Jul 10, 2026, 6 insiders at Amylyx Pharmaceuticals, Inc. (AMLX) reported 29 transactions on record: 2 purchases and 27 sales. In total, insiders bought $152.2K and sold $7.92M, a net selling position of $7.77M. 5 insiders also sold within a 30-day window around Mar 2, 2026.

Net Direction
Net Seller
$152.2K bought vs $7.92M sold
Cluster Signal
0 buy, 3 sell
2+ insiders trading same direction within 30 days
See what institutional investors are doing โ†’
Cluster Activity

Multiple insiders trading the same direction in a short window is generally read as a stronger signal than any single trade alone.

Buy clusters
None on record.
Sell clusters
5 insiders ยท Sep 30, 2025 to Sep 30, 2025
Klee Justin B., Mazzariello Gina, FRATES JAMES M, Cohen Joshua B, Bedrosian Camille L
4 insiders ยท Jan 6, 2026 to Feb 2, 2026
FRATES JAMES M, Cohen Joshua B, Klee Justin B., Mazzariello Gina
5 insiders ยท Feb 23, 2026 to Mar 2, 2026
Mazzariello Gina, Klee Justin B., Cohen Joshua B, Bedrosian Camille L, FRATES JAMES M
Biggest Transactions on Record
DateInsiderRoleTypeSharesValue
Jan 15, 2026Cohen Joshua BCo-Chief Executive OfficerSale136.2K$1.85M
Jan 15, 2026Klee Justin B.Co-Chief Executive OfficerSale136.2K$1.85M
Sep 30, 2025Klee Justin B.Co-Chief Executive OfficerSale30.0K$431.0K
Sep 30, 2025Cohen Joshua BCo-Chief Executive OfficerSale29.9K$429.5K
Mar 2, 2026Cohen Joshua BCo-Chief Executive OfficerSale29.3K$424.1K
Every Insider Trading This Stock

Every insider with activity on record, most recently active first.

InsiderRoleLast ActivityDateLatest Known Holding
Mazzariello GinaChief Legal OfficerSaleJul 10, 2026179.1K
Firestone KarenDirectorPurchaseMay 21, 202666.9K
Klee Justin B.Co-Chief Executive OfficerSaleMar 2, 20263.33M
FRATES JAMES MChief Financial OfficerSaleMar 2, 2026165.6K
Cohen Joshua BCo-Chief Executive OfficerSaleMar 2, 20263.33M
Bedrosian Camille LChief Medical OfficerSaleMar 2, 2026169.3K
Complete Insider Transaction History

Every purchase and sale on record, deduplicated. "52w range" shows where that price sat in the trailing year at the time, and "Since" shows the paper return from that price to today.

DateInsiderRoleTypeSharesPriceValue52w RangeSince
Jul 10, 2026Mazzariello GinaChief Legal OfficerSale15.0K$17.61$264.1K92%+97.3%
Jul 9, 2026Mazzariello GinaChief Legal OfficerSale15.0K$18.32$274.7K97%+89.6%
May 21, 2026Firestone KarenDirectorPurchase3.8K$13.51$51.3K68%+157.1%
Mar 2, 2026Mazzariello GinaChief Legal OfficerSale6.8K$14.52$99.4K88%+139.3%
Mar 2, 2026FRATES JAMES MChief Financial OfficerSale7.9K$14.52$114.9K88%+139.3%
Mar 2, 2026Bedrosian Camille LChief Medical OfficerSale6.5K$14.58$94.2K88%+138.3%
Mar 2, 2026Cohen Joshua BCo-Chief Executive OfficerSale29.3K$14.48$424.1K88%+139.9%
Mar 2, 2026Klee Justin B.Co-Chief Executive OfficerSale29.3K$14.47$423.8K88%+140.1%
Feb 23, 2026Mazzariello GinaChief Legal OfficerSale3.4K$14.14$48.4K78%+145.7%
Feb 2, 2026Klee Justin B.Co-Chief Executive OfficerSale15.5K$14.69$227.6K84%+136.5%
Feb 2, 2026Mazzariello GinaChief Legal OfficerSale3.4K$14.65$50.5K84%+137.1%
Feb 2, 2026Cohen Joshua BCo-Chief Executive OfficerSale15.5K$14.68$227.6K84%+136.6%
Feb 2, 2026FRATES JAMES MChief Financial OfficerSale3.6K$14.65$52.1K84%+137.1%
Jan 16, 2026Klee Justin B.Co-Chief Executive OfficerSale2.0K$13.89$27.7K88%+150.1%
Jan 16, 2026Cohen Joshua BCo-Chief Executive OfficerSale2.0K$13.83$27.3K88%+151.2%
Jan 15, 2026Klee Justin B.Co-Chief Executive OfficerSale136.2K$13.58$1.85M82%+155.8%
Jan 15, 2026Cohen Joshua BCo-Chief Executive OfficerSale136.2K$13.59$1.85M82%+155.6%
Jan 6, 2026Klee Justin B.Co-Chief Executive OfficerSale7.7K$11.09$85.6K66%+213.3%
Jan 6, 2026Cohen Joshua BCo-Chief Executive OfficerSale7.7K$11.09$85.6K66%+213.3%
Jan 6, 2026FRATES JAMES MChief Financial OfficerSale3.3K$11.11$37.0K66%+212.7%
Dec 23, 2025Firestone KarenDirectorPurchase8.1K$12.45$100.8K73%+179.0%
Dec 1, 2025Bedrosian Camille LChief Medical OfficerSale6.6K$14.35$94.4K88%+142.1%
Sep 30, 2025Bedrosian Camille LChief Medical OfficerSale12.0K$14.58$175.5K89%+138.3%
Sep 30, 2025Cohen Joshua BCo-Chief Executive OfficerSale29.9K$14.35$429.5K89%+142.1%
Sep 30, 2025FRATES JAMES MChief Financial OfficerSale10.6K$14.65$154.7K89%+137.1%
Sep 30, 2025Mazzariello GinaChief Legal OfficerSale8.8K$14.58$128.7K89%+138.3%
Sep 30, 2025Klee Justin B.Co-Chief Executive OfficerSale30.0K$14.38$431.0K89%+141.6%
Aug 13, 2025Mazzariello GinaChief Legal OfficerSale15.0K$8.34$125.0K98%+316.5%
Aug 12, 2025Mazzariello GinaChief Legal OfficerSale15.0K$8.07$121.1K97%+330.5%

52w range and paper return are only computed for transactions with a date that lines up with price history on record.

Frequently Asked Questions
Are insiders buying or selling AMLX stock?

On record between Aug 12, 2025 and Jul 10, 2026, Amylyx Pharmaceuticals, Inc. insiders made 2 purchases ($152.2K) and 27 sales ($7.92M), a net selling position of $7.77M.

Has there been cluster buying or selling at AMLX?

No buying clusters (2+ insiders within 30 days) on record. 5 insiders sold within 30 days around Sep 30, 2025; 4 insiders sold within 30 days around Feb 2, 2026; 5 insiders sold within 30 days around Mar 2, 2026.

What is the largest recent insider transaction at AMLX?

The largest transaction on record is Cohen Joshua B (Co-Chief Executive Officer), a sale of $1.85M on Jan 15, 2026.

Does a 10b5-1 automatic trading plan explain AMLX's insider sales?

This data does not indicate whether a given sale was part of a pre-scheduled Rule 10b5-1 plan, that detail is not captured in the transaction data available here.

Sourced from insider transaction filings for AMLX. Transactions are deduplicated where the same trade appears in both a summarized and a raw filing format. This page does not detect Rule 10b5-1 scheduled trading plans, that detail is not available in the underlying data, and does not track individual insiders' historical trading accuracy, since most insiders here have too few transactions on record for that to be meaningful. This is historical data, not investment advice. Read disclaimer โ†’